Author's Reply by Hayden, Deborah
PLoS Medicine  |  www.plosmedicine.org 0561
Correspondence
Open access, freely available online
June 2005  |  Volume 2  |  Issue 6  |  e129
Medical Decision Making: 
The Family–Doctor–Patient Triad
Fawad Aslam, Omar Aftab, Naveed Z. Janjua
The importance of a person-centred approach and the 
intricacies of risk communication have recently been well 
described in PLoS Medicine [1,2]. The applicability of the 
patient-centred approach to Eastern countries, however, has 
cultural, religious, and practical impediments that demand 
careful consideration. The bulk of the world population 
lives outside the United States and western Europe. Unlike 
in the West where the patient takes centre stage by both 
tradition and law, the family–doctor–patient triad is the 
norm in Eastern states, in general, and Pakistan in particular 
[3–8].
Pakistan is a predominantly Muslim country of 150 million 
people. About half the population is uneducated, and 
more than a third lives below the poverty line. There is one 
doctor for every 1,432 patients, compared to one doctor for 
every 390 patients in the US. The health-insurance system 
is virtually nonexistent, and there is no concept of assisted-
care living, with the care of the elderly largely taking place 
at homes by their families. Strongly held religious beliefs 
and cultural views govern everyday life and dictate the roles 
of every member of the society. Families consist of well-knit, 
supportive, and collectively earning interdependent members 
who take mutual decisions on all matters pertaining to life 
and death [3,4]. The elder members of the family command 
the greatest respect and authority. The family unit is the 
functional unit of the society, the dynamics of which need 
attention and respect. 
Strong family systems and the authoritative position of the 
doctor are the governing forces of medical decision making 
in these countries. Illiteracy, poverty, poor awareness of 
patient’s rights, and a lack of accountability for physicians are 
factors conducive to such a practice. With this background, 
the role of the patient is limited. Health expenditure is borne 
by the family, giving it a central role in decision making. 
The concept of the ﬁ  nancial survival of the family is a harsh 
reality [3,4]. The health-care costs of one seriously ill member 
may jeopardize the survival of others by draining the limited 
resources. Due to familial, moral, and monetary support, the 
patient relinquishes the responsibility of decision making and 
gives the primary role to the family or the doctor. Women, 
for example, may not give consent unless they get approval 
from their spouses [5]. In the case of women, who may have 
a lesser say in the patriarchal family system, the doctor should 
strive for active participation. Sometimes the family aims to 
protect the patient from stress by withholding information, 
and in terminal illnesses, the doctor and family act in concert 
to conceal complete information from the patient. They, for 
example, may not mention the word cancer to patients who 
have malignancies [9]. 
In contrast to Western practice, the role of the doctor is 
authoritative. Doctors are regarded as instruments of God 
and given the ﬁ  nal authority in decision making [3,4,10]. 
In such circumstances, doctors are likely to take decisions 
unilaterally. When they do involve patients in decision 
making, physicians accept the centrality of families, with 
some considering patients and families as one [5]. One 
worry regarding communication of harm is of losing patients 
to other physicians with a more reassuring “nothing will 
go wrong” attitude [5]. It is also said that more time and 
patience are required to explain things to the illiterate. It 
is perhaps impractical, therefore, to expect overworked 
and underpaid physicians to practice risk communication 
according to the book. 
Thus, the concept of individual centrality that is so 
elementary in the West stands challenged in the East. 
Research is needed to formulate appropriate strategies of 
risk communication. Areas needing research include the 
patient’s concept of autonomy, the role of the family as 
perceived by patients and doctors, the existing practices 
of medical decision making, and the training of doctors in 
communicating risk. 
An economically sound and literate population, properly 
trained doctors, and institutional checks and balances are 
essential prerequisites for establishing decision making with 
parity of partners. The need is to ﬁ  nd a middle ground where 
not only the family unit is respected, but the patient also plays 
a proactive role. A dynamic balance between cultural values 
of caring and the possibility of a more individualistic role 
in health care is needed and is, indeed, attainable. Doctors, 
being the most inﬂ  uential component of the family–doctor–
patient triad, can play a signiﬁ  cant role in bringing about this 
change.  
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Malaria Diagnosis and Treatment: 
One Size Does Not Fit All
Chris Drakeley, Roly Gosling, Hugh Reyburn 
Icke and colleagues highlight an online and CD-ROM source 
available for the teaching of malaria diagnosis [1]. While this 
is a commendable initiative that provides open access to badly 
needed training materials, we feel that it is overambitious to 
propose this Web site (which gives equal weight to diagnosis, 
treatment, and chemoprophylaxis) as a resource that can 
be equally relevant to the issues of travel-related malaria, to 
which the Web site primarily applies, and the problems of 
malaria diagnosis and treatment in sub-Saharan Africa, which 
are described as the primary focus in the PLoS Medicine   article 
[1].
The microscopic diagnosis of malaria is indeed an 
important resource in Africa to which the large majority of 
health facilities do not have access. Even where microscopy 
is available, there is evidence of substantial overdiagnosis of 
malaria and that better access to malaria microscopy may 
not result in better targeting of antimalarials [2,3]. What 
data there is on the accuracy of slide results suggest that 
microscope quality, preparation of blood ﬁ  lms, and quality of 
reagents are at least as important in constraining the quality 
of results as the ability of slide readers to identify Plasmodium 
parasites from high-quality thin blood ﬁ  lms [4–6]. In fact, 
thick blood ﬁ  lms are the norm in Africa, thin ﬁ  lms being 
almost exclusively conﬁ  ned to research, yet these are in the 
small minority on the Web site.
P. falciparum is overwhelmingly the dominant Plasmodium 
species seen in Africa, and training guides that try to give 
a “global overview” run the risk of giving a misleading 
impression of the relative importance of the four species in 
any given setting where malaria is endemic. The only actual 
setting where all species of malaria might be seen relatively 
frequently would be in travel clinics in developed countries. 
This point might seem obvious, but for many junior 
laboratory technicians in Africa hungry for scarce training 
opportunities it is potentially distracting and confusing.
The problems of simultaneously addressing the issues 
of malaria in endemic areas of Africa and in travellers 
from resource-rich countries are particularly applicable 
to malaria treatment. On the Web site, among the drugs 
recommended for the treatment of non-severe malaria are 
quinine, atovaquone/proguanil hydrochloride, meﬂ  oquine, 
and two tetracyclines. In Africa quinine is reserved for severe 
malaria and is associated with a high rate of failure due 
to poor adherence in outpatients; atovaquone/proguanil 
hydrochloride and meﬂ  oquine are not widely used because 
of their high cost; and tetracyclines are contraindicated in 
children and pregnant women, who bear the overwhelming 
burden of malaria. 
The Web site describes criteria for severe malaria that are 
not appropriate for Africa. Thus, cerebral malaria, jaundice, 
renal failure, and lactic acidosis (impossible to detect in 
most African hospitals where “respiratory distress” is the 
equivalent criterion) are all listed ahead of severe anaemia, 
the most common manifestation of severe malaria in Africa. 
Repeated convulsions are not mentioned, presumably 
because they are rare among travellers with malaria, but they 
are common among children in Africa and are associated 
with a poor outcome. Renal failure as a manifestation of 
severe malaria is mentioned second but is very uncommon 
in Africa [7,8]. 
The apparently large numbers of African health-care 
workers who have accessed this site might legitimately feel 
confused by some of these descriptions, and there is no 
indication of which, if any, sections apply to Africa and which 
to travellers. While many will interpret the information 
critically, others may not, especially when English is not 
their ﬁ  rst language and where there is a tendency to accept 
didactic sources in preference to what is obvious from 
personal or local experience. 
The diagnostic component of the Web site has important 
potential as a training tool, but we feel that signiﬁ  cant 
modiﬁ  cation and more explicit indication of information that 
is country-speciﬁ  c are needed before its use is likely to result 
in improved standards of care in African hospitals and clinics.
It is true that Internet technologies can “revolutionise 
information technology…for healthcare professionals in 
developing countries”. The World Health Organization 
and others already have very extensive Web sites that are 
contributing to this. Searching the Internet on “malaria 
diagnosis” reveals a number of sites, many with excellent 
sections, but one is struck by the lack of clarity deﬁ  ning 
the target audience and context of the problem. For much 
information available on the Web this may not matter, but for 
malaria we feel it does.  
Chris Drakeley (chris.drakeley@lshtm.ac.uk)
Roly Gosling
Hugh Reyburn 
London School of Hygiene and Tropical Medicine 
London, United Kingdom 
Joint Malaria Programme
Moshi, Tanzania
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Authors’ Reply:  Teaching Health Workers 
Malaria Diagnosis
With reference to the letter commenting on our paper 
[1] from Drakeley and colleagues [2], they have some 
justiﬁ  cation in stating that one size does not ﬁ  t all. However 
our Web site, which is the basis for their comment, was 
originally designed on a wholly voluntary basis for Australia. 
We have been overwhelmed by the interest and acceptance 
of this site worldwide. Not only have we had more than 
750,000 visitors to the site but have issued free CD-ROMs to 
institutions in 149 countries. 
The fact that it was warmly embraced by so many others 
from around the world bears testimony to its usefulness 
as, indeed, do the tens of thousands of letters and E-
mails thanking us for our efforts. We have made some 
modiﬁ  cations on our annual update in response to 
suggestions and changes in approach. The main section 
of interest has been the section on diagnosis, testing, and 
teaching, and perhaps the reason for this is the high quality 
of the illustrations. One only has to look at the site to 
recognize that we have not given equal weight to all sections, 
as Drakeley and colleagues point out. The emphasis is on 
diagnosis, testing, and teaching. Many large organizations 
have requested a substantial number of copies of the CD-
ROM, and in Germany one organization has been printing 
its own (with permission). We are aware of some superb CD-
ROMs on malaria put out from other sources, but they are 
expensive for organizations with a very small budget.  
We accept that diagnosis by thick ﬁ  lm is the norm in Africa 
and a number of other countries and, in fact, have spent 
many years ourselves diagnosing malaria from thick ﬁ  lms in 
India and Southeast Asia. We have described how to make 
thick ﬁ  lms and have provided a picture. We have mentioned 
the staining of ﬁ  lms, but we have not described how to 
prepare the stains because we considered that outside our 
brief. It is important with Web sites to be concise, otherwise 
they won’t be read. The actual diagnosis of malaria is the 
same for Africa, India, South America, and Southeast Asia, 
and it is the proper diagnosis that we believe is paramount. 
We know that language can be a serious problem. We have 
provided a version in French and Spanish. The French 
version we are told is useful for certain parts of Africa. When 
other languages have been requested, we have suggested that 
a small booklet should be written in the local language by 
those with local knowledge. 
In regards to the comments on treatment, this section was 
written by T. M. E. Davis, who holds the Chair of Medicine 
at the University of Western Australia and is a consultant on 
malaria to Thailand and Cambodia. If we sought an expert on 
treatment for every endemic region, we would never get the 
material into print. One is not always able to use the drugs of 
choice in Southeast Asia because up to 50% of antimalarials 
sold in some areas are fake. It has been stated that children 
should not be given tetracyclines, but that has already been 
made very clear on the site. 
We are aware that the site needs to take into account 
various interests and situations, which is why we have included 
our E-mail addresses on the site. We presume that as experts 
in the ﬁ  eld Drakeley and colleagues would have been aware 
of the site either in Tanzania or the London School of 
Tropical Medicine, where a number of CD-ROMs have been 
requested and sent. We hope and expect that eventually 
a group with the enthusiasm of these correspondents will 
accept the challenge and produce a site that will overcome 
the problems that are the cause of their concern. We fully 
understand the difﬁ  culty of doing this on a voluntary basis. In 
the meantime, we will continue to service the site and hope 
that the very large number of users will continue to ﬁ  nd it 
helpful. Finally, we state once again that if concise suggestions 
for improvements are sent to us by E-mail we will give them 
serious consideration. Our E-mail contact is now sandy.
treadgold@health.wa.gov.au.  
Graham Icke 
Richard E. Davis 
Royal Perth Hospital
Perth, Western Australia, Australia
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Allocating Antiretrovirals in South 
Africa: Using Modeling to Determine 
Treatment Equity
David P. Wilson, Sally M. Blower
Recently PLoS Medicine published our paper entitled 
“Designing Equitable Antiretroviral Allocation Strategies in 
Resource-Constrained Countries” [1]. We were disappointed 
to ﬁ  nd that the editorial perspective written by the World 
Health Organization (WHO) ethicists regarding our paper 
[2] was based upon a substantial misunderstanding of our 
novel quantitative analyses and our important results. Hence, 
they misunderstood the signiﬁ  cance of the health-policy 
implications of our results. Thus, we wish to correct the 
record.
Firstly, Capron and Reis [2] misunderstood our 
quantitative analyses. They stated that “Wilson and Blower 
developed a mathematical model that could inform policy-
makers’ decisions regarding the optimal distribution of 
treatment sites to ensure equal access by all individuals 
infected with HIV.” However, our model does not determine 
the optimal distribution of treatment sites. As we clearly 
state in our paper [1] (and is also stated in the synopsis [3]), 
we developed a model that policy makers can use to make 
decisions regarding how to achieve the optimal allocation of 
scarce antiretrovirals among the available health-care facilities 
(HCFs) if the objective is to ensure treatment equity. We also 
calculated how the optimal allocation of antiretrovirals would 
vary if the number of HCFs utilized increased and/or the size 
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of the catchment area that each HCF services increased [1]. 
Thus, we took the treatment sites (i.e., HCFs) as given, and we 
used their speciﬁ  c spatial location in South Africa as inputs 
to our model in order to determine optimal antiretroviral 
allocation strategies under a variety of conditions.
Secondly, Capron and Reis [2] misunderstood our 
important results. They stated that “applying this tool to 
the South-African province of KwaZulu–Natal, Wilson and 
Blower were able to conﬁ  rm mathematically the intuitive 
assumption that using a maximum number of centers, at the 
least possible distance from most affected populations, would 
lead to the greatest fairness in the geographical distribution 
of ART [antiretroviral therapy].” We agree that if these had 
been our results, they would have been trivial and obvious. 
However, Capron and Reis [2] did not discuss our actual 
results: we determined how to decide how many drugs to 
allocate to each of the available HCFs in order to achieve 
an optimal allocation if the objective is to ensure treatment 
equity. This is a very complex problem and the antiretroviral 
allocation strategies that we calculated (by using our model) 
to be optimal are very complex (see Figure 3 in our paper, 
which graphically shows the proportion of drugs that should 
be allocated to each of the available HCFs). Furthermore, 
we also determined what catchment area each HCF should 
service; speciﬁ  cally, we calculated that each HCF should serve 
(if the objective is to achieve treatment equity) a catchment 
area of 40–60 km. Thus, our results demonstrate (to our 
knowledge for the ﬁ  rst time) that patients infected with 
HIV will have to travel extremely large distances (i.e., 40  –60 
km) in order to receive antiretrovirals, if the objective is 
to achieve treatment equity in South Africa. We stress that 
currently it is unknown what the actual size of the catchment 
area is around HCFs in South Africa. Catchment areas may 
in fact be very small. Thus, we suggested [1] that a primary 
goal should be to obtain empirical data of the distances that 
patients in South Africa are willing (or able) to travel in order 
to receive antiretrovirals. We have been the ﬁ  rst to provide a 
quantitative assessment of the necessary size of the catchment 
area, and our results have identiﬁ  ed that there is an urgent 
need to collect these critical data for quantifying the size of 
the catchment areas around HCFs. We have determined that 
the size of the catchment area will be a critical component 
in the ability to achieve treatment equity in South Africa. 
We also compared the optimal antiretroviral allocation 
strategies that we calculated with the current plan of the 
South African government for allocating antiretrovirals [4], 
and we determined that the current antiretroviral allocation 
strategies in South Africa will not achieve treatment equity. 
Taken together, our quantitative results are novel and 
controversial,  providing important quantitative insights into 
a complex public-health problem.
We applaud the ambitious “3 by 5” WHO target for 
the antiretroviral rollout. However, the WHO has not yet 
devised a quantitative policy for determining how to allocate 
antiretrovirals in situations where the demand for drugs 
greatly exceeds the supply [5]. Health-policy ofﬁ  cials in 
each country will have to make these important and difﬁ  cult 
decisions, and they will all make different decisions based 
upon what objectives they wish to optimize and prioritize. 
There are a multitude of factors to consider (these factors 
are well described in the recent Institute of Medicine report 
[6]). We stress that the alternative to a quantitative rational 
approach for allocating scarce resources is an ad hoc 
approach, which is how the scarce supply of antiretrovirals 
is currently being distributed in many resource-constrained 
countries. Our operations research modeling approach is 
based upon spatial heterogeneity in the distribution of HCFs 
in South Africa and the spatial heterogeneity of the HIV-
infected population. The most important “real world” result 
is that we show that what the South African government is 
currently doing is inequitable. We show them how to achieve 
equity, if they wish to do so. We hope that our novel approach 
for deciding how to allocate antiretrovirals will be of use to 
the WHO and also to the relevant authorities in the many 
resource-constrained countries who will soon have to make 
very difﬁ  cult decisions as to who lives and who dies. Our 
analysis is to our knowledge the ﬁ  rst analysis to show how a 
rational and scientiﬁ  c solution can be reached for deciding 
how to allocate a limited amount of antiretrovirals, if the goal 
is to achieve treatment equity. Clearly, other goals must be 
taken into consideration (and our model can be modiﬁ  ed to 
include these other goals); however, we hope that treatment 
equity will be a very high priority during the antiretroviral 
rollout that is just beginning.  
David P. Wilson
Sally M. Blower (sblower@mednet.ucla.edu)
University of California
Los Angeles, California, United States of America
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Authors’ Reply
In response to our commentary [1] on their paper, 
“Designing Equitable Antiretroviral Allocation Strategies in 
Resource-Constrained Countries” [2], Wilson and Blower 
assert that we misunderstood both their analysis and the 
importance of their results [3]. Rather than “setting the 
record straight,” what may be needed is more effort to bridge 
the differences in disciplinary approach that create a greater 
appearance of disagreement than is actually the case.
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On a factual level, we believe Wilson and Blower’s 
results were appropriately described for the purposes of 
our commentary. As their letter points out, they applied 
the operations research methods to model the allocation 
of antiretrovirals (ARVs) among 17 health-care centers in 
KwaZulu–Natal, based on a hypothetical distribution of 
HIV/AIDS among the communities in that province. Their 
article characterizes this as “an elegant and simple theoretical 
framework,” but they object to our concluding that it could 
“inform policy-makers’ decisions regarding the location of 
HIV services,” since they took the treatment sites as given. Yet 
their article compared the alternatives of using all 54 centers 
in the province, at one extreme, and of using only a single 
treatment site (in Durban), at the other extreme; in each 
case, the possibility of allocating to a larger number of centers 
is equivalent to the creation of additional centers closer to 
remote groups of patients. 
Wilson and Blower write that geographic accessibility is 
improved if the number of health-care facilities is increased, 
and they calculated that it would be optimal if all 54 facilities 
in the province of KwaZulu–Natal distributed the medicines, 
instead of just 17. We took this result to conﬁ  rm the need to 
reach out and build capacity. We are sorry if we were mistaken 
in assuming that Wilson and Blower would want to see their 
stated objective of ensuring fair distribution applied in the real-
world context of many poor countries with a high HIV burden 
and where fairness in ARV care cannot be achieved solely by 
allocating resources among the existing sites.
A wider gap in perception can be seen in Wilson and 
Blower’s repeated conﬂ  ation of “optimal,” “equal,” and 
“equitable,” combined with their suggestion that decision 
makers who fail to apply their model must be following an 
“ad hoc approach.” The central point of our commentary 
was that various ethical theories reach very different 
conclusions about what result would be optimal, and that 
even among those aiming to achieve the greatest equity 
(rather than some other optimum), many would not take 
equality as the measure of equity. Wilson and Blower 
themselves recognize that apparent equality of access (in 
terms of distance to treatment) needs further study to 
determine whether patients can in fact access treatment. 
We need to know whether some distances are simply too far 
for patients to travel for chronic care, and when distances 
of equal length affect access very differently because 
of the characteristics of particular patient populations, 
transportation systems, and so forth.
Wilson and Blower seem unwilling to accept the notion 
that, in the furtherance of a rational strategy to achieve 
equity, some health authorities might decide, for example, 
to allocate a disproportionate share of ARVs to traditionally 
disadvantaged populations. Wilson and Blower’s model 
could still be useful in allocating resources among the 
centers chosen (or established) to reach the target 
population, but the calculation would have to take account 
of more information about the centers and the population, 
lest assumptions about catchment areas produce a formal 
equality that does not translate into actual equality in 
access, much less into equitable access in light of all relevant 
factors. 
Plainly, we share Wilson and Blower’s aim of optimizing 
countries’ responses to the tragedy of treatable, but 
untreated, HIV/AIDS. Any tools that are useful to that 
end are welcome. But besides using models to distribute 
ARVs in a way that optimizes spatial equality, governments 
that want to achieve equity will need also to overcome 
nongeographic  barriers to accessing treatment. These 
include ignorance, stigma, discrimination, and outright 
criminalization of vulnerable groups, as well as fees at point 
of service that are prohibitive for the poor. All of these are 
given attention within the context of the “3 by 5” program 
of the World Health Organization and the United Nations 
Joint Programme on HIV/AIDS, including in the guidance 
document on equitable access to ARV treatment cited in our 
commentary [4].  
Alexander M. Capron (caprona@who.int)
Andreas Reis
World Health Organization
Geneva, Switzerland
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The Debate over Placebo-Controlled 
Trials
Frankllin Miller
Turner and Tramèr provide a cogent argument in favor of 
the ethical use of placebo controls despite “proven effective 
treatment” [1]. However, they are wide of the mark citing the 
APPROVe trial in support of their position. Because there 
is no established treatment to prevent adenomatous polyps, 
few commentators would have any objections to the use of 
placebo controls in this study. Nevertheless, they are right to 
suggest that it would have been desirable to have included 
a placebo control in the VIGOR study to provide a more 
rigorous assessment of safety. Whether, all things considered, 
a placebo control would have been ethical in this study of 
treatment for rheumatoid arthritis is debatable.
Another issue not discussed in this PLoS Medicine Debate 
is the value of placebo controls in early “proof of concept” 
efﬁ  cacy trials, despite the existence of established treatment. 
The efﬁ  ciency of seeking a rigorous efﬁ  cacy signal before 
moving on to larger-scale trials (and exposing as few subjects 
as possible to drugs that might not work or turn out to be 
toxic) is a valid ethical reason for using placebo controls, 
provided subjects are not exposed to undue risks of harm 
from withholding established treatment [2].  
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Authors’ Reply
We appreciate Dr. Miller’s contribution to this debate [1]. 
Whether one uses his phrase “established treatment” or 
“proven therapy,” we urge caution in using such a litmus test 
to decide whether the use of placebo is or is not acceptable. 
Such terms beg to be deﬁ  ned carefully. Should nonsteroidal 
anti-inﬂ  ammatory drugs be considered “proven” for arthritis, 
despite their problems with assay sensitivity [2,3]? Dr. Miller 
states that there is no established treatment for adenomatous 
polyps. However, there is evidence from epidemiological 
studies and clinical trials supporting the use of aspirin 
and other nonsteroidal anti-inﬂ  ammatory drugs for this 
condition [4–10]. Armed with such evidence—whether it 
qualiﬁ  es aspirin as “proven therapy” is open to subjective 
interpretation—many placebo opponents, we maintain, 
would argue for an active-controlled design as a more ethical 
alternative to the placebo-controlled design actually used in 
APPROVe [11]. 
Dr. Miller focuses on the question of defending the use 
of placebo in the APPROVe study. This focus reﬂ  ects the 
prevailing bias, which is to choose when it is acceptable to 
use placebo rather than to choose when it is acceptable to 
omit placebo. This bias is evident in the current version of 
the Declaration of Helsinki, with wording such as, “Extreme 
care must be taken in making use of placebo-controlled 
trials.” Thus, the use of placebo is typically presumed “guilty 
until proven innocent,” while active-controlled designs are 
presumed “innocent until proven guilty.” The declaration 
is silent on the possibility that omitting placebo can lead to 
problems, too, as we have now witnessed with Vioxx. 
So perhaps the more important question should be 
whether it was defensible to exclude placebo in the VIGOR 
study. Dr. Miller acknowledges that placebo would have 
provided a better assessment of the safety signal in the 
VIGOR study. Indeed, because placebo was not used, the 
authors were able to plausibly conclude that the difference 
between the two groups was due to naproxen causing beneﬁ  t 
rather than to Vioxx causing harm [12]. (The plausibility 
of this conclusion has since been questioned [13,14].) This 
misleading safety signal only delayed the withdrawal of 
Vioxx. Its design was superﬁ  cially ethical, but science was not 
advanced, and the public health was ill-served. 
One might protest that these comments are made with the 
beneﬁ  t of hindsight. It is true that the medical community 
at large did not become aware of this safety issue until 
September 2004, when the results of the placebo-controlled 
APPROVe study were made public and Vioxx was withdrawn. 
However, according to David Graham’s testimony to the 
United States Senate [15] and a report on internal Merck 
documents [16], there was good reason for concern about a 
possible safety signal before 1999, when Vioxx was approved 
and recruitment for VIGOR began [15]. 
If the VIGOR study had included a placebo arm, the truth 
about Vioxx could have been learned in February 2001 
instead of September 2004 [14]. That is over 180 weeks 
during which the now infamous “two to four jumbo jetliners” 
were allowed to continue “dropping from the sky every week” 
[15]. Using the midpoints of Graham’s range estimates, 
this works out to 94,500 excess heart attacks and strokes, 
including 33,000 deaths, in the US alone.
The authors of the VIGOR study said, “We could not 
include a placebo group” [12]. Was the idea of including 
a placebo arm suggested but rejected as “unethical,” even 
though rescue medication could have been used? Or did 
they take the path of least resistance in the interest of rapid 
institutional review board approval and ease of patient 
recruiting? Whatever the reason, the decision to omit placebo 
led to ambiguity and inaction.
In clinical trials, whether one looks at efﬁ  cacy (please see 
our opening argument in this debate [17]) or safety, omitting 
placebo often muddies the scientiﬁ  c waters and places the 
public health at increased risk. Good science and good ethics 
cannot be divorced from one another. We believe these 
considerations should factor into discussions on the ethics of 
clinical trial design. Before we experience another Vioxx, we 
hope that a future version of the Declaration of Helsinki will 
add, “Extreme care must be taken when omitting placebo.”  
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Call for Biohistory Guidelines
Jordan Paradise
I am writing in response to an essay published in the most 
recent issue of PLoS Medicine by Deborah Hayden, entitled 
“Alas, Poor Yorick: Digging Up the Dead to Make Medical 
Diagnoses” [1]. As a co-author of the Science piece with Lori 
B. Andrews that Hayden references, I am troubled by her 
comment on our article. Nowhere in that article, “Ethics. 
Constructing Ethical Guidelines for Biohistory” [2], do we 
suggest that genetic testing be done on deceased individuals 
for historically signiﬁ  cant questions. In fact, we speciﬁ  cally 
highlight some of the ethical, legal, social, and scientiﬁ  c 
issues that such testing raises and recommend that guidelines 
be developed in order to monitor current research that is 
being undertaken in this area. The article does not advocate 
biohistorical research. This distinction is very important and 
one that is quite evident upon a careful reading of our article.  
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Author’s Reply
The excellent article by Jordan Paradise, Lori B. Andrews, 
and colleagues, “Ethics. Constructing Ethical Guidelines 
for Biohistory” [1], neither advocates nor argues against 
biohistorical research; instead, it points out that such 
investigations are currently taking place without guidelines—
ethical, scientiﬁ  c, moral, or religious. The question remains: 
if such guidelines were to be established, what individuals, 
institutions, governments, medical examiners, family 
members, or intrepid biographers are to be given permission? 
Who is to decide what is “historically signiﬁ  cant”? Not to 
mention the meta-question: who is to decide who is to decide? 
I apologize to the authors if my brief comments [2] implied 
that they took a position on this issue.  
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